The distribution of CHA2DS2-VASc scores was 0, 1, 2, 3, 4, 5, 6, and 7 points in 76 (23%), 60 (18%), 69 (21%), 69 (21%), 28 (8%), 23 (7%), 6 (2%), and 1 (0.3%) patients, respectively. The annual rates of symptomatic ischemic stroke were 0%, 0.60%, 0.95%, 1.96%, 5.45%, 9.06%, and 13.7%when the CHA2DS2-VASc score was 0, 1, 2, 3, 4, 5, and 鈮? points, respectively (p < 0.001) and those of cardiovascular events including hospitalization for thromboembolism, heart failure and cardiovascular death were 0%, 1.43%, 1.50%, 2.52%, 10.14%, 12.85%, and 17.13%when the CHA2DS2-VASc score was 0, 1, 2, 3, 4, 5 and 鈮? points, respectively (p < 0.001). Higher CHA2DS2-VASc scores were associated with greater annual rates of ischemic stroke and cardiovascular events. In a multivariate logistic regression analysis adjusted for the potentially confounding variables, the CHA2DS2-VASc score was associated with symptomatic ischemic stroke (odds ratio 7.051, 95%confidence interval 3.76-13.22, p < 0.001) and cardiovascular events (odds ratio 3.448, 95%confidence interval 2.33-5.11, p < 0.001).
In Japanese patients with paroxysmal AF, the CHA2DS2-VASc score is a useful scheme for risk stratification of ischemic stroke and cardiovascular events.